PHARMACY POLICY STATEMENT
Ohio Medicaid

<table>
<thead>
<tr>
<th>DRUG NAME</th>
<th>Prolia (denosumab)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BILLING CODE</td>
<td>J0897</td>
</tr>
<tr>
<td>BENEFIT TYPE</td>
<td>Medical</td>
</tr>
<tr>
<td>SITE OF SERVICE ALLOWED</td>
<td>Office/Outpatient Hospital</td>
</tr>
<tr>
<td>STATUS</td>
<td>Prior Authorization Required</td>
</tr>
</tbody>
</table>

Prolia (denosumab) was initially approved by the FDA in 2010. It is a monoclonal antibody that inhibits the RANK ligand (RANKL) and is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture, treatment to increase bone mass in men with osteoporosis at high risk for fracture, and treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. It is also approved to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer and for treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Prolia (denosumab) will be considered for coverage when the following criteria are met:

**Osteoporosis in Postmenopausal Women**

For initial authorization:
1. Member is a postmenopausal woman; AND
2. Member has a diagnosis of osteoporosis, as evidenced by one of the following:
   a) Bone mineral density (BMD) T-score –2.5 or below in the lumbar spine, femoral neck, total proximal femur, or 1/3 radius;
   b) Low-trauma spine or hip fracture (regardless of BMD);
   c) Osteopenia (T-score between –1 and –2.5) with a fragility fracture of proximal humerus, pelvis, or distal forearm;
   d) Osteopenia (T-score between –1 and –2.5) with FRAX fracture probability of ≥ 20% for major osteoporotic fracture or ≥ 3% for hip fracture; AND
3. Member meets one of the following:
   a) Member has had an inadequate response to at least 12 months of an oral bisphosphonate (e.g., alendronate, risedronate) or an IV bisphosphonate (e.g., zoledronic acid (Reclast), ibandronate) OR
   b) Member has very high risk for fracture (e.g., having multiple fractures, very low T score (-3.0 or below), T-score -2.5 or below plus fractures, fractures while taking osteoporosis drug, FRAX > 30% for major osteoporosis fracture or 4.5% for hip fracture) AND has had a trial of zoledronic acid.

4. **Dosage allowed/Quantity limit**: 60 mg subQ every 6 months. (1 syringe (1 mL) per 6 months)

_If all the above requirements are met, the medication will be approved for 12 months._
For **reauthorization**:  
1. Chart notes have been provided showing stable or increase in bone mineral density, with no evidence of new fractures or vertebral fracture progression.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.*

---

**Osteoporosis in Men**

For **initial** authorization:

1. Member is a male 18 years of age or older; AND  
2. Medication is being used to treat osteoporosis; AND  
3. Member is at high-risk for fracture as evidenced by one of the following:  
   a) Hip or vertebral fracture without major trauma  
   b) BMD of the spine, femoral neck, and/or total hip is 2.5 SD or more below the mean of normal young white males (T-score -2.5 or less)  
   c) T-score between −1.0 and −2.5 in the spine, femoral neck, or total hip plus a 10-yr risk of experiencing any fracture ≥ 20% or 10-yr risk of hip fracture ≥ 3% using FRAX; AND  
4. Member has had an inadequate response to at least 12 months of an oral bisphosphonate (e.g., alendronate, risedronate) or an IV bisphosphonate (e.g., zoledronic acid (Reclast)), unless not tolerated or contraindicated.  
5. **Dosage allowed/Quantity limit:** 60 mg subQ every 6 months. (1 syringe (1 mL) per 6 months)

*If all the above requirements are met, the medication will be approved for 12 months.*

For **reauthorization**:

1. Chart notes have been provided showing stable or increase in bone mineral density, with no evidence of new fractures or vertebral fracture progression.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.*

---

**Glucocorticoid-Induced Osteoporosis**

For **initial** authorization:

1. Member is 18 years of age or older; AND  
2. Medication is being used to treat Glucocorticoid-induced osteoporosis in a member who is initiating or continuing systemic glucocorticoids equivalent to daily 7.5 mg or greater of prednisone and will remain on therapy for at least 6 months; AND  
3. Member is at high-risk for fracture as evidenced by at least one of the following:  
   a) Prior osteoporotic fragility fracture(s)  
   b) Postmenopausal female or male age 50 and older with hip or spine bone mineral density (BMD) T-score -2.5 or below  
   c) Age 40 or older with FRAX 10-year risk of:  
      i) Major osteoporotic fracture of 20% or above; OR  
      ii) Hip fracture of 3% or above; AND  
4. Member has had an inadequate response to at least 12 months of an oral bisphosphonate (e.g., alendronate, risedronate) or an IV bisphosphonate (e.g., zoledronic acid (Reclast)), unless not tolerated or contraindicated.  
5. **Dosage allowed/Quantity limit:** 60 mg subQ every 6 months. (1 syringe (1 mL) per 6 months)

*If all the above requirements are met, the medication will be approved for 12 months.*
For **reauthorization**:  
1. Chart notes have been provided showing stable or increase in bone mineral density, with no evidence of new fractures or vertebral fracture progression.  

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.*

### Bone Loss (prostate cancer)

For **initial** authorization:  
1. Member is a male 18 years of age or older; **AND**  
2. Member has a diagnosis of non-metastatic prostate cancer; **AND**  
3. Member is receiving androgen deprivation therapy (e.g., goserelin, leuprolide, degarelix); **AND**  
4. Member is at high risk for fracture, as defined by one of the following:  
   a) T-score less than -2.5 (osteoporosis) in the femoral neck, total hip, or lumbar spine  
   b) Prior fragility fracture(s)  
   c) FRAX score of ≥ 20% for major osteoporotic fracture or ≥ 3% for hip fracture; **AND**  
5. Member has had an inadequate response to 12 months of an oral bisphosphonate (e.g., alendronate, risedronate) or an IV bisphosphonate (e.g., zoledronic acid (Reclast)), unless not tolerated or contraindicated.  
6. **Dosage allowed/Quantity limit:** 60 mg subQ every 6 months. (1 syringe (1 mL) per 6 months)  

*If all the above requirements are met, the medication will be approved for 12 months.*

For **reauthorization**:  
1. Member continues to be at high risk for fracture due to taking androgen deprivation therapy; **AND**  
2. Chart notes have been provided showing stable or increase in bone mineral density, with no evidence of new fractures or vertebral fracture progression.  

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.*

### Bone Loss (breast cancer)

For **initial** authorization:  
1. Member is a postmenopausal female; **AND**  
2. Member has a diagnosis of breast cancer; **AND**  
3. Member is currently receiving an adjuvant aromatase inhibitor (e.g., anastrozole, letrozole); **AND**  
4. Member is at high risk for fracture, as defined by one of the following:  
   a) T-score < -2.0 in the femoral neck, total hip, or lumbar spine  
   b) Has two or more of the following risk factors: prior fragility fracture(s), parental hip fracture, diabetes, 2 or more falls in the past year, rheumatoid arthritis, BMI < 20, current smoking, more than 2 alcoholic drinks per day, greater than 7.5 mg/day glucocorticoid use > 3 months  
   c) Has T-score <1.0 plus one of the above risk factors; **AND**  
5. Member has had an inadequate response to 12 months of an oral bisphosphonate (e.g., alendronate, risedronate) or an IV bisphosphonate (e.g., zoledronic acid (Reclast)), unless not tolerated or contraindicated.  
6. **Dosage allowed/Quantity limit:** 60 mg subQ every 6 months. (1 syringe (1 mL) per 6 months)  

*If all the above requirements are met, the medication will be approved for 12 months.*
For **reauthorization**:
1. Member continues to be at high risk for fracture due to receiving aromatase inhibitor therapy; AND
2. Chart notes have been provided showing stable or increase in bone mineral density, with no evidence of new fractures or vertebral fracture progression.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.*

CareSource considers Prolia (denosumab) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

<table>
<thead>
<tr>
<th>DATE</th>
<th>ACTION/DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/19/2019</td>
<td>New policy for Prolia created</td>
</tr>
<tr>
<td>08/13/2020</td>
<td>For osteoporosis: added age requirement; removed Appendix of risk factors for fracture; added diagnostic criteria for GC-induced; removed exclusions (uncorrected hypocalcemia, dental disease, Xgeva within past 6 months); removed vitamin D &amp; calcium requirement; removed reasons oral bisphosphonate cannot be used; changed trial to 12 months of oral or IV bisphosphonate; changed approval length to 12 months. For bone loss due to cancer drugs: added age requirement; redefined diagnostic requirements according to latest guidelines; removed exclusions (uncorrected hypocalcemia, dental disease, Xgeva within past 6 months); removed vitamin D &amp; calcium requirement; trial specified to be 12 months or oral or IV bisphosphonate; changed approval length to 12 months.</td>
</tr>
</tbody>
</table>

References:


OH-MED-P-366685


Effective date: 10/01/2022
Revised date: 4/26/2022